Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J van der Mooren

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
Maturitas|November 20, 1998
Hormone replacement therapy in postmenopausal women with specific risk factors for coronary artery diseaseM J van der Mooren, V Mijatovic, W M van Baal, et al.
Journal of Internal Medicine|January 20, 2006
Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled studyM O Verhoeven, M Hemelaar, M J van der Mooren, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|July 10, 1999
Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protectionV Mijatovic, M J van der Mooren, C D Stehouwer, et al.
European Radiology|January 1, 1997
Mammographic changes in postmenopausal women on hormonal replacement therapyR C Marugg, M J van der Mooren, J H Hendriks, et al.
Obstetrics and Gynecology|October 8, 1999
Hormone replacement therapy and plasma homocysteine levelsW M van Baal, R G Smolders, M J van der Mooren, et al.
Acta Endocrinologica|August 1, 1993
Differences in serum lipids, lipoproteins, sex hormone binding globulin and testosterone between the follicular and the luteal phase of the menstrual cycleC P Schijf, M J van der Mooren, W H Doesburg, et al.
The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception|December 18, 2003
A comparative study of the effects of gestodene 60 microg/ethinylestradiol 15 microg and desogestrel 150 microg/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolismM J van der Mooren, C Klipping, B van Aken, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|December 15, 1993
A 2-year study on the beneficial effects of 17 beta-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesteroneM J van der Mooren, P N Demacker, C M Thomas, et al.
Human Reproduction (Oxford, England)|February 28, 2006
No increase in C-reactive protein levels during intranasal compared to oral hormone therapy in healthy post-menopausal womenM Hemelaar, P Kenemans, C G Schalkwijk, et al.
Fertility and Sterility|September 26, 2000
Gonadotropin-releasing hormone agonist plus "add-back" hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trialH R Franke, P H van de Weijer, T M Pennings, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Maturitas|November 20, 1998
Hormone replacement therapy in postmenopausal women with specific risk factors for coronary artery diseaseM J van der Mooren, V Mijatovic, W M van Baal, et al.
Journal of Internal Medicine|January 20, 2006
Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled studyM O Verhoeven, M Hemelaar, M J van der Mooren, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|July 10, 1999
Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protectionV Mijatovic, M J van der Mooren, C D Stehouwer, et al.
European Radiology|January 1, 1997
Mammographic changes in postmenopausal women on hormonal replacement therapyR C Marugg, M J van der Mooren, J H Hendriks, et al.
Obstetrics and Gynecology|October 8, 1999
Hormone replacement therapy and plasma homocysteine levelsW M van Baal, R G Smolders, M J van der Mooren, et al.
Acta Endocrinologica|August 1, 1993
Differences in serum lipids, lipoproteins, sex hormone binding globulin and testosterone between the follicular and the luteal phase of the menstrual cycleC P Schijf, M J van der Mooren, W H Doesburg, et al.
The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception|December 18, 2003
A comparative study of the effects of gestodene 60 microg/ethinylestradiol 15 microg and desogestrel 150 microg/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolismM J van der Mooren, C Klipping, B van Aken, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|December 15, 1993
A 2-year study on the beneficial effects of 17 beta-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesteroneM J van der Mooren, P N Demacker, C M Thomas, et al.
Human Reproduction (Oxford, England)|February 28, 2006
No increase in C-reactive protein levels during intranasal compared to oral hormone therapy in healthy post-menopausal womenM Hemelaar, P Kenemans, C G Schalkwijk, et al.
Fertility and Sterility|September 26, 2000
Gonadotropin-releasing hormone agonist plus "add-back" hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trialH R Franke, P H van de Weijer, T M Pennings, et al.
Pageof 6